keyword
https://read.qxmd.com/read/38419410/pharmacological-treatment-of-obesity-in-adults-in-norway-2004-2022
#1
JOURNAL ARTICLE
Paz Lopez-Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, Kristina Slåtsve, Hanne L Gulseth, Haakon E Meyer, Kari Anne Sveen, Elisabeth Qvigstad, Kari Furu
AIMS: To describe trends in the use of anti-obesity drugs in Norway during the period 2004-2022. MATERIALS AND METHODS: We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18-79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18-29 years and 10-year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti-obesity drug and on the cost of the anti-obesity drugs since 2017...
February 28, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38268718/injectable-weight-loss-medications-in-plastic-surgery-what-we-know-perioperative-considerations-and-recommendations-for-the-future
#2
JOURNAL ARTICLE
Elizabeth S O'Neill, Aaron L Wiegmann, Naomi Parrella, Troy Pittman, Keith Hood, David Kurlander
Obesity is a major epidemic plaguing American society. Injectable subcutaneous medications initially designed for use in type 2 diabetes management, such as semaglutide and other glucagon-like peptide-1 receptor agonists, are rapidly gaining popularity for their effects on weight. These drugs (Ozempic, Wegovy, Saxenda, and Mounjaro) are ubiquitous on social media and are promoted by celebrities across all demographics. "Ozempic face" and "Ozempic butt" are now mainstream concepts highlighting the morphologic changes that occur with these medications...
January 2024: Plastic and Reconstructive Surgery. Global Open
https://read.qxmd.com/read/38241775/glp-1-agonists-a-review-for-emergency-clinicians
#3
REVIEW
Brit Long, Jessica Pelletier, Alex Koyfman, Rachel E Bridwell
INTRODUCTION: Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use. OBJECTIVE: This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians. DISCUSSION: GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake...
January 12, 2024: American Journal of Emergency Medicine
https://read.qxmd.com/read/38133594/tirzepatide-zepbound-for-chronic-weight-management
#4
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 25, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38125231/awareness-of-urinary-stone-risk-factors-among-the-adult-population-of-jazan-saudi-arabia-a-cross-sectional-study
#5
JOURNAL ARTICLE
Essa Adawi, Naif K Mahzara, Rafa Hadaddi, Seham Ageeli, Tahani Altubayqi, Esaam Moafa, Sultan Althurwi, Alyaj A Hakami, Reem Qahtani, Abdulaziz M Kariri, Sumayyah Jafar, Taif Kobal, Rafa Alqaari
BACKGROUND: Urolithiasis, a common clinical condition, has seen a global increase in prevalence in recent years. Urinary stones are common in hot climate areas like Saudi Arabia. This study aimed to assess the prevalence and awareness of risk factors for urinary stones in Jazan, Saudi Arabia. METHODS: A cross-sectional study was conducted among 1000 Jazan adults between January and June 2022. A questionnaire was used to collect data on sociodemographics, urinary stone diagnosis, and awareness of risk factors...
November 2023: Curēus
https://read.qxmd.com/read/38103152/popularity-of-surgical-and-pharmacological-obesity-treatment-methods-searched-by-google-users-the-retrospective-analysis-of-google-trends-statistics-in-2004-2022
#6
JOURNAL ARTICLE
Mikołaj Kamiński, Maja Miętkiewska-Dolecka, Matylda Kręgielska-Narożna, Paweł Bogdański
PURPOSE: Many individuals search for obesity treatment options on the Internet. We aimed to analyze the popularity of pharmacological and surgical obesity treatment methods searched by Google users. MATERIAL AND METHODS: We used Google Trends to identify topics representing the following: recommended surgical methods (n = 9), recommended pharmacological methods (n = 10), and not recommended pharmacological methods (n = 34)...
December 16, 2023: Obesity Surgery
https://read.qxmd.com/read/38012508/liraglutide-3-0%C3%A2-mg-saxenda%C3%A2-for-weight-loss-and-remission-of-pre-diabetes-real-world-clinical-evaluation-of-effectiveness-among-patients-awaiting-bariatric-surgery
#7
JOURNAL ARTICLE
Rebekah Wilmington, Arash Ardavani, Amelia Simenacz, Carol Green, Iskandar Idris
OBJECTIVE: The effectiveness of liraglutide 3.0 mg (Saxenda) therapy to induce weight loss among obese patients prior to bariatric surgery remains uncertain. METHODS: Clinical data was retrospectively obtained from patients with prediabetes (HbA1c 42-47 mmol/mol) and selected patients on the waiting list for bariatric surgery at the Royal Derby Hospital. Clinical data was collected retrospectively at 6, 12, 26 and 52 week intervals. The outcomes included mean weight change, proportion of patients achieving ≥ 5% and ≥ 10% weight loss and achieving HbA1c reduction to normal range values...
November 28, 2023: Obesity Surgery
https://read.qxmd.com/read/38000977/factors-contributing-to-whether-or-not-people-with-obesity-undergo-bariatric-surgery
#8
JOURNAL ARTICLE
Chi-Whan Choi, Daniel Cunha, Christine Helfrich, Simone V Gill
BACKGROUND: Bariatric surgery has been suggested as a safe and effective way to treat obesity by facilitating weight loss, but factors that predict the likelihood of bariatric surgery are unknown. The objective of this study was to describe factors associated with individuals with obesity that influence their decision to undergo bariatric surgery. SUBJECTS AND METHODS: The study design was a cross-sectional study and participants were recruited via a survey link posted on the Obesity Action Coalition website...
November 23, 2023: Obesity Research & Clinical Practice
https://read.qxmd.com/read/37983121/in-brief-gi-effects-of-glp-1-receptor-agonists
#9
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 27, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37944862/impact-of-a-pharmacist-led-weight-management-service-in-a-cardiology-clinic
#10
JOURNAL ARTICLE
Madison Yates, Megan Supple, Melissa Maccia
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management require frequent dose titration, patient education, and insurance coverage navigation, which pharmacists are well equipped to manage. Data are lacking regarding the benefit of a pharmacist-managed service using GLP-1 RAs for weight loss in a high-risk cardiac population. OBJECTIVE: This study aimed to evaluate the impact of a pharmacist-led weight loss service within a cardiology clinic using GLP-1 RAs and lifestyle counseling in patients with overweight and obesity...
November 8, 2023: Journal of the American Pharmacists Association: JAPhA
https://read.qxmd.com/read/37915772/effect-of-liraglutide-on-fat-mass-percentage-among-overweight-and-obese-adults-with-type-2-diabetes-a-systematic-review
#11
REVIEW
Alanoud Aladel, Jamilah Aljaouni, Reem Basaad
BACKGROUND: Obesity and type 2 diabetes mellitus (T2DM) are two global public health problems. Liraglutide, a glucagon-like peptide 1 analogue (GLP-1), is considered an effective option for weight loss. Hence, it is meaningful to understand the impact of GLP-1 therapy on body composition, particularly fat mass percentage (%), in determining health risks associated with obesity. The current meta-analysis and systematic review aimed to appraise and summarize available studies regarding the efficacy of liraglutide on fat mass (%), anthropometrics and glycemic control...
2023: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/37821008/trends-in-glucagon-like-peptide-1-receptor-agonist-use-2014-to-2022
#12
JOURNAL ARTICLE
Jonathan H Watanabe, Jimmy Kwon, Bin Nan, Andrew Reikes
BACKGROUND: Recent Food and Drug Administration approvals of glucagon-like peptide 1 (GLP-1) receptor agonists linked to substantial weight loss have generated interest in demand projections. However, a longitudinal analysis in a large, diverse, current, real-world database has not been published. OBJECTIVES: The study objective was to determine user frequency of GLP-1 receptor agonist products overall and by type 2 diabetes (T2D), cardiovascular disease (CVD), and overweight or obese status...
October 10, 2023: Journal of the American Pharmacists Association: JAPhA
https://read.qxmd.com/read/37712012/a-narrative-review-of-approved-and-emerging-anti-obesity-medications
#13
REVIEW
Semira Abdi Beshir, Asim Ahmed Elnour, Aadith Soorya, Affana Parveen Mohamed, Sheron Sir Loon Goh, Nadia Hussain, Amal H I Al Haddad, Faizah Hussain, Israa Yousif Khidir, Zainab Abdelnassir
BACKGROUND: Recently, many drugs have been approved for halting overweight and obesity-few types of research shifted to using Anti-obesity medications (AOM) solely for well-being and shape-keeping. OBJECTIVE: This narrative review's objective was to explore the use of AOM in relation to their medical indications, efficacy, and cardiovascular safety. METHODS AND MATERIALS: We have conducted a narrative review of the literature on approved/non-approved AOM used for obesity and overweight...
October 2023: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/37664345/knowledge-and-attitude-of-the-general-population-in-saudi-arabia-toward-weight-management-medications-wmms-a-cross-sectional-study
#14
JOURNAL ARTICLE
Malak A Algarni, Ameera Ali M Algarni, Waleed A Alqarni, Ahmad Y Alqassim
BACKGROUND:  Over the past decades, the global prevalence of obesity has tripled, with the Kingdom of Saudi Arabia experiencing a notably higher rate of increase. While lifestyle modifications remain the first line of treatment, pharmacological interventions are often employed when dietary and exercise interventions prove insufficient. However, safety concerns, misuse, and limited knowledge about weight management medications (WMMs) pose serious challenges. OBJECTIVES:  The objectives of this study were to determine the level of knowledge and examine attitudes towards WMMs among the general population, and to explore the factors associated with these knowledge levels and attitude patterns...
August 2023: Curēus
https://read.qxmd.com/read/37465801/first-reported-case-of-dulaglutide-induced-acute-pancreatitis-with-normal-serum-lipase-level
#15
Mohammad Shahbazi, Zainab Qudsiya, Aboud Fahel, Afshin Amini, Tariq Tanoli
Dulaglutide is being extensively used for non-insulin-dependent diabetes mellitus and congestive heart failure and is also being used as an off-label weight loss aid. Due to its wide use, we had to shed some light on this rare finding of normal lipase level in a patient with signs and symptoms suggestive of acute pancreatitis. A high index of clinical suspicion for acute pancreatitis despite normal lipase should warrant a low threshold for radiological imaging to rule it out.
June 2023: Curēus
https://read.qxmd.com/read/36945294/weight-loss-of-over-100-lbs-in-a-patient-of-prader-willi-syndrome-treated-with-glucagon-like-peptide-1-glp-1-agonists
#16
Sana Ahmed, Arooj Naz, Mahnoor K
Prader-Willi syndrome (PWS) is the most common genetic obesity syndrome. The clinical features of this condition include childhood obesity, hyperphagia, infantile hypotonia, hypogonadism, short stature, and characteristic facial features. The leading cause of morbidity and mortality in PWS is hyperphagia and resultant obesity. Here, we highlight the effectiveness of glucagon-like peptide-1 (GLP-1) agonists by reporting an interesting case of successful rapid weight loss in an adult with PWS using GLP-1 agonists - exenatide and liraglutide...
February 2023: Curēus
https://read.qxmd.com/read/36757837/in-brief-semaglutide-wegovy-for-weight-loss-in-children
#17
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 20, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36514273/investigating-the-potential-non-authorized-use-of-two-different-formulations-of-liraglutide-in-europe-a-real-world-drug-utilization-study
#18
JOURNAL ARTICLE
Paolo Sbraccia, Jens Aberle, Anne Helene Olsen, Naveen Rathor, Atheline Major-Pedersen
AIMS: Liraglutide is marketed in Europe as Victoza® (1.2 mg/1.8 mg), indicated for glycaemic control in type 2 diabetes, and Saxenda® (3.0 mg), indicated for weight management in adults with obesity. We performed a post-authorization safety study (PASS) to assess the in-market use of Saxenda® and Victoza® according to approved indications and posology. MATERIALS AND METHODS: This retrospective, non-interventional study was conducted at 41 sites between December 2016 and May 2019...
December 13, 2022: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/36384763/drugs-for-type-2-diabetes
#19
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 14, 2022: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36277516/fda-approved-pharmacotherapy-for-weight-loss-over-the-last-decade
#20
REVIEW
Zarwa Idrees, Ivan Cancarevic, Li Huang
Obesity is a recently defined illness whose diagnosis and treatment continue to be stigmatized. Currently, due to lifestyle changes brought on by technological advancements and the wide availability and affordability of high-calorie foods, millions of people around the world suffer from obesity and/or its sequelae. Finding adequate prevention and treatment options would therefore lead to massive improvements in the duration and quality of life of affected individuals. In this review, we searched the PubMed database for studies exploring the safety and efficacy of the five medications currently approved by the FDA for the treatment of obesity...
September 2022: Curēus
keyword
keyword
74710
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.